We had the pleasure of welcoming Slovak alpine skiing champion Petra Vlhová to our SanaClis...
Speak to an Expert
Reach out to our team of experts to discuss your project needs.
Providing unparalleled added value to ensure success from early onset
Decentralized trials are fast becoming the industry's focus, disrupting the conventional centralized approach utilized for many years. Yet, despite the industry moving towards decentralized trials, there is no unified standard nor regulatory framework across any of the major regions. For a Direct to Patient/Site to Patient model to be implemented successfully, early engagement is crucial to ensure correct protocol development, design and provision of the necessary procedures ready for the IMPD submission.
SanaClis is able to fully support Direct to Patient, Site to Patient Delivery and Direct from Patient in all major regions, such as the US, Europe, APAC, LATAM and South Africa in respective countries in which DtP is permitted by the local regulatory authority
Our experience and knowledge of the entire clinical operational aspects, in addition to our global supply chain/sourcing/DtP capabilities, ensures complete coverage of important local requirements and protocol development considerations, to support the successful execution of the decentralized project.
All key internal teams at SanaClis, from the supply chain, sourcing and clinical operation departments, work collaboratively and together to ensure no stone is left unturned and enable the successful planning and execution of your DCT study. Clear visibility and expertise across all areas, makes SanaClis unrivalled.